BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8725888)

  • 1. Histopathological effects of androgen deprivation in prostatic cancer.
    Civantos F; Soloway MS; Pinto JE
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.
    Civantos F; Marcial MA; Banks ER; Ho CK; Speights VO; Drew PA; Murphy WM; Soloway MS
    Cancer; 1995 Apr; 75(7):1634-41. PubMed ID: 8826921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant hormonal deprivation before radical prostatectomy.
    Schulman CC; Sassine AM
    Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
    Andros EA; Danesghari F; Crawford ED
    Clin Invest Med; 1993 Dec; 16(6):510-5. PubMed ID: 7516835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
    Wieder JA; Soloway MS
    J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
    Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
    Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
    Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.
    Ferguson J; Zincke H; Ellison E; Bergstrahl E; Bostwick DG
    Urology; 1994 Jul; 44(1):91-5. PubMed ID: 8042266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy.
    Solomon MH; McHugh TA; Dorr RP; Lee F; Siders DB
    Clin Invest Med; 1993 Dec; 16(6):532-8. PubMed ID: 8013157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy.
    Lee F; Siders DB; McHug TA; Solomon MH; Klamerus ML
    Anticancer Res; 1997; 17(3A):1507-10. PubMed ID: 9179187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Histologic regression of localized prostatic tumor with neoadjuvant hormonal therapy].
    López López C; Quilez Fenoll JM; Gómez Ruiz JJ; López López AF; Romero Maroto YJ
    Arch Esp Urol; 1996 Oct; 49(8):819-23. PubMed ID: 9065279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
    Villavicencio Mavrich H; Chéchile Toniolo G; Salinas Duffo D; Muñoz Plaza J; Sorraca Ibáñez YJ
    Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.